Clinical management of the hypereosinophilic syndromes

Expert Review of Hematology

Volumn 5, Issue 3, 2012, Pages 275-290

  Cogan, Elie ^a   Roufosse, Florence ^a,b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

anti IL 5; chronic eosinophilic leukemia; hypereosinophilic syndrome; imatinib; lymphocytic variant hypereosinophilic syndrome

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CORTICOSTEROID; DASATINIB; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; NILOTINIB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGRAPHY; BIOPSY; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW BIOPSY; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE CLASSIFICATION; DRUG TOLERANCE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIC LEUKEMIA; FLOW CYTOMETRY; GASTROINTESTINAL TOXICITY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOGLOBULIN BLOOD LEVEL; KARYOTYPE; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MEDICAL TERMINOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHENOTYPE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THORAX RADIOGRAPHY;

ADRENAL CORTEX HORMONES; ANTIBODIES; ENZYME INHIBITORS; HUMANS; HYDROXYUREA; HYPEREOSINOPHILIC SYNDROME; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTERLEUKIN-5; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STEM CELL TRANSPLANTATION;

EID: 84863793709     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.14     Document Type: Review

References (89)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54(1), 1-27 (1975).
2. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann. Intern. Med. 68(6), 1220-1229 (1968).
3. Klion AD, Bochner BS, Gleich GJ et al. Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. J. Allergy Clin. Immunol. 117(6), 1292-1302 (2006).
4. Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N. Engl. J. Med. 330(8), 535-538 (1994).
5. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N. Engl. J. Med. 341(15), 1112-1120 (1999).
6. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348(13), 1201-1214 (2003).
7. Simon HU, Rothenberg ME, Bochner BS et al. Refining the definition of hypereosinophilic syndrome. J. Allergy Clin. Immunol. 126(1), 45-49 (2010).
8. Gotlib J. World Health Organizationdefined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am. J. Hematol. 86(8), 677-688 (2011).
9. Valent P, Gleich GJ, Reiter A et al. Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field. Expert Rev. Hematol. 5(2), 157-176 (2012).
10. Simon D, Simon HU. Eosinophilic disorders. J. Allergy Clin. Immunol. 119(6), 1291-300; quiz 1301 (2007).
11. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J. Allergy Clin. Immunol. 126(1), 39-44 (2010).
12. Klion A. Hypereosinophilic syndrome: Current approach to diagnosis and treatment. Annu. Rev. Med. 60, 293-306 (2009).
13. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol. Allergy Clin. North Am. 27(3), 389-413 (2007).
14. Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol. Allergy Clin. North Am. 27(3), 377-388 (2007).
15. 4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood 114(14), 2969-2983 (2009).
16. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 83(10), 2759-2779 (1994).
17. Ogbogu PU, Bochner BS, Butterfield JH et al. Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy. J. Allergy Clin. Immunol. 124(6), 1319.e3-1325.e3 (2009).
18. Parrillo JE, Fauci AS, Wolff SM. The hypereosinophilic syndrome: Dramatic response to therapeutic intervention. Trans. Assoc. Am. Physicians 90, 135-144 (1977).
19. Butterfield JH. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol. Allergy Clin. North Am. 27(3), 493-518 (2007).
20. Roufosse F, Schandené L, Sibille C et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br. J. Haematol. 109(3), 540-548 (2000).
21. 4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES). Scand. J. Immunol. 72(4), 372-373 (2010).
22. Vandenberghe P, Wlodarska I, Michaux L et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18(4), 734-742 (2004).
23. Dahabreh IJ, Giannouli S, Zoi C, Zoi K, Voulgarelis M, Moutsopoulos HM. Management of hypereosinophilic syndrome: A prospective study in the era of molecular genetics. Medicine (Baltimore) 86(6), 344-354 (2007).
24. 4+ lymphocytosis of TH2/TH0 type. Int. J. Hematol. 75(3), 281-284 (2002).
25. Means-Markwell M, Burgess T, deKeratry D et al. Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15. N. Engl. J. Med. 342(21), 1568-1571 (2000).
26. Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann. Intern. Med. 121(9), 648-653 (1994).
27. Malbrain ML, Van den Bergh H, Zachée P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: Complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br. J. Haematol. 92(1), 176-183 (1996).
28. Zielinski RM, Lawrence WD. Interferonalpha for the hypereosinophilic syndrome. Ann. Intern. Med. 113(9), 716-718 (1990).
29. Fruehauf S, Fiehn C, Haas R, Doehner H, Hunstein W. Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy. Acta Haematol. 89(2), 91-93 (1993).
30. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am. J. Hematol. 58(2), 137-141 (1998).
31. 4+ T cells. J. Immunol. 164(5), 2296-2302 (2000).
32. 4+ T cells. J. Clin. Invest. 97(2), 309-315 (1996).
33. Schandené L, Roufosse F, De Lavareille A et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 96(13), 4285-4292 (2000).
34. Savage DG, Antman KH. Imatinib mesylate - A new oral targeted therapy. N. Engl. J. Med. 346(9), 683-693 (2002).
35. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359(9317), 1577-1578 (2002).
36. Klion AD, Robyn J, Akin C et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103(2), 473-478 (2004).
37. Jovanovic JV, Score J, Waghorn K et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109(11), 4635-4640 (2007).
38. Klion AD, Robyn J, Maric I et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRApositive chronic eosinophilic leukemia: Implications for optimal dosing. Blood 110(10), 3552-3556 (2007).
39. Helbig G, Moskwa A, Hus M et al. Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRa-positive chronic eosinophilic leukaemia. Cancer Chemother. Pharmacol. 67(4), 967-969 (2011).
40. Mahon FX, Réa D, Guilhot J et al.; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11(11), 1029-1035 (2010).
41. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 19(2), 286-287 (2005).
42. Salemi S, Yousefi S, Simon D et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy 64(6), 913-918 (2009).
43. Score J, Curtis C, Waghorn K et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20(5), 827-832 (2006).
44. Albano F, Anelli L, Zagaria A et al. Extramedullary molecular evidence of the 5′KIAA1509/3′PDGFRB fusion gene in chronic eosinophilic leukemia. Leuk. Res. 32(2), 347-351 (2008).
45. Curtis CE, Grand FH, Musto P et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br. J. Haematol. 138(1), 77-81 (2007).
46. Baccarani M, Cilloni D, Rondoni M et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalphapositive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9), 1173-1179 (2007).
47. Helbig G, Hus M, Halasz M et al. Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Med. Oncol. 29(2), 1073-1076 (2012).
48. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalphanegative hypereosinophilic syndrome. Leuk. Res. 33(8), 1127-1129 (2009).
49. Musto P, Falcone A, Sanpaolo G et al. Heterogeneity of response to imatinibmesylate (glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis. Leuk. Lymphoma 45(6), 1219-1222 (2004).
50. Vaklavas C, Tefferi A, Butterfield J et al. 'Idiopathic' eosinophilia with an occult T-cell clone: Prevalence and clinical course. Leuk. Res. 31(5), 691-694 (2007).
51. Christoforidou A, Kotsianidis I, Margaritis D, Anastasiadis A, Douvali E, Tsatalas C. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate. Am. J. Hematol. 87(1), 131-132 (2012).
52. Pitini V, Arrigo C, Azzarello D et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 102(9), 3456-3457; author reply 3457 (2003).
53. Cools J, Stover EH, Boulton CL et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRainduced myeloproliferative disease. Cancer Cell 3(5), 459-469 (2003).
54. Lierman E, Folens C, Stover EH et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 108(4), 1374-1376 (2006).
55. Stover EH, Chen J, Lee BH et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106(9), 3206-3213 (2005).
56. Metzgeroth G, Erben P, Martin H et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 26(1), 162-164 (2012).
57. Ikezoe T, Togitani K, Tasaka T, Nishioka C, Yokoyama A. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leuk. Res. 34(8), e200-e201 (2010).
58. Lierman E, Michaux L, Beullens E et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 23(5), 845-851 (2009).
59. Baumgartner C, Gleixner KV, Peter B et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp. Hematol. 36(10), 1244-1253 (2008).
60. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356(9248), 2144-2148 (2000).
61. Stein ML, Villanueva JM, Buckmeier BK et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J. Allergy Clin. Immunol. 121(6), 1473-1483, 1483.e1 (2008).
62. Garrett JK, Jameson SC, Thomson B et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J. Allergy Clin. Immunol. 113(1), 115-119 (2004).
63. Plötz SG, Simon HU, Darsow U et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N. Engl. J. Med. 349(24), 2334-2339 (2003).
64. Kim YJ, Prussin C, Martin B et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J. Allergy Clin. Immunol. 114(6), 1449-1455 (2004).
65. Rothenberg ME, Klion AD, Roufosse FE et al.; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med. 358(12), 1215-1228 (2008).
66. Roufosse F, De Lavareille A, Schandené L et al. Mepolizumab as a corticosteroidsparing agent in lymphocytic variant hypereosinophilic syndrome. J. Allergy Clin. Immunol. 126(4), 828.e3-835.e3 (2010).
67. Kolbeck R, Kozhich A, Koike M et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J. Allergy Clin. Immunol. 125(6), 1344.e2-1353.e2 (2010).
68. Busse WW, Katial R, Gossage D et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a Phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 125(6), 1237.e2-1244.e2 (2010).
69. Marshall GM, White L. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome. Am. J. Pediatr. Hematol. Oncol. 11(2), 178-183 (1989).
70. Van Slyck EJ, Adamson TC 3rd. Acute hypereosinophilic syndrome. Successful treatment with vincristine, cytarabine, and prednisone. JAMA 242(2), 175-176 (1979).
71. Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: A case report. Br. J. Haematol. 127(5), 477 (2004).
72. Verstovsek S, Tefferi A, Kantarjian H et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin. Cancer Res. 15(1), 368-373 (2009).
73. Wagner LA, Speckart S, Cutter B, Gleich GJ. Treatment of FIP1L1/PDGFRAnegative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. J. Allergy Clin. Immunol. 123(6), 1407-1408 (2009).
74. Sefcick A, Sowter D, DasGupta E, Russell NH, Byrne JL. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br. J. Haematol. 124(4), 558-559 (2004).
75. Bernengo MG, Quaglino P, Comessatti A et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: Clinical and immunologic findings in 14 patients. Haematologica 92(6), 784-794 (2007).
76. Halaburda K, Prejzner W, Szatkowski D, Limon J, Hellmann A. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: Long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant. 38(4), 319-320 (2006).
77. Bergua JM, Prieto-Pliego E, Román-Barberá A et al. Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation. Ann. Hematol. 87(11), 937-938 (2008).
78. Nair P, Ochkur SI, Protheroe C, Simms E, Lee NA, Lee JJ. The identification of eosinophilic gastroenteritis in prednisonedependent eosinophilic bronchitis and asthma. Allergy Asthma. Clin. Immunol. 7(1), 4 (2011).
79. Dallos T, Heiland GR, Strehl J et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum. 62(11), 3496-3503 (2010).
80. Kakinuma T, Sugaya M, Nakamura K et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: Serum TARC levels reflect the disease activity of mycosis fungoides. J. Am. Acad. Dermatol. 48(1), 23-30 (2003).
81. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann. Intern. Med. 97(1), 78-92 (1982).
82. Lefebvre C, Bletry O, Degoulet P et al. [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases]. Ann. Med. Interne (Paris) 140(4), 253-257 (1989).
83. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q. J. Med. 52(205), 1-22 (1983).
84. Simon HU, Yousefi S, Dommann-Scherrer CC et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J. Exp. Med. 183(3), 1071-1082 (1996).
85. Bassan R, Locatelli G, Borleri G, Salvi A, Barbui T. Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes. Haematologica 89(2), 238-239 (2004).
86. González Delgado P, De La Sen Fernández ML, Soriano Gomis V, Pérez Crespo M, Muñoz Ruiz C, Hernández Niveiro E. Cyclical hypereosinophilia with skin manifestations and a clonal T-cell population. J. Investig. Allergol. Clin. Immunol. 18(5), 401-403 (2008).
87. Zaccaria E, Drago F, Rossi E, Rebora A. T-cell-associated hypereosinophilic syndrome: Case report and an appraisal of the new classification. J. Eur. Acad. Dermatol. Venereol. 22(9), 1120-1121 (2008).
88. Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, Majewski M, Kyrcz-Krzemien S. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica 94(9), 1236-1241 (2009).
89. Galimberti S, Ciabatti E, Ottimo F et al. Cell clonality in hypereosinophilic syndrome: What pathogenetic role? Clin. Exp. Rheumatol. 25(1), 17-22 (2007).